Sprycel FDA Approval History
FDA Approved: Yes (First approved June 28, 2006)
Brand name: Sprycel
Generic name: dasatinib
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Sprycel (dasatinib) is a kinase inhibitor indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Development timeline for Sprycel
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.